The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer [vol 45, pg 507, 2022]

被引：1
|
作者：
Khatoon, Elina [1 ,2 ]
Hegde, Mangala [1 ,2 ]
Kumar, Aviral [1 ,2 ]
Daimary, Uzini Devi [1 ,2 ]
Sethi, Gautam [3 ,4 ]
Bishayee, Anupam [5 ]
Kunnumakkara, Ajaikumar B. [1 ,2 ]
机构：
[1] Indian Inst Technol IIT Guwahati, Dept Biosci & Bioengn, Canc Biol Lab, Gauhati 781039, Assam, India
[2] Indian Inst Technol IIT Guwahati, DBT AIST Int Ctr Translat & Environm Res DAICENTER, Gauhati 781039, Assam, India
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore
[4] Natl Univ Singapore, NUS Ctr Canc Res, Yong Loo Lin Sch Med, Singapore, Singapore
[5] Lake Erie Coll Osteopath Med, Coll Osteopath Med, Bradenton, FL 34211 USA
来源：
ARCHIVES OF PHARMACAL RESEARCH | 2023年 / 46卷 / 03期
关键词：
D O I：
10.1007/s12272-023-01434-5
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [31] Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma
    Wang, Huamin
    Su, Xiaoping
    Yang, Mingjin
    Chen, Taoyong
    Hou, Jin
    Li, Nan
    Cao, Xuetao
    ONCOIMMUNOLOGY, 2015, 4 (10):
  • [32] Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma (vol 4, e1031440, 2015)
    Wang, H.
    Su, X.
    Yang, M.
    Chen, T.
    Hou, J.
    Li, N.
    Cao, X.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [33] STAT3 as a potential therapeutic target in ALDI+ and CD44+/CD24+ stem cell-like pancreatic cancer cells
    Lin, Li
    Jou, David
    Wang, Yina
    Ma, Haiyan
    Liu, Tianshu
    Fuchs, James
    Li, Pui-Kai
    Lu, Jiagao
    Li, Chenglong
    Lin, Jiayuh
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) : 2265 - 2274
  • [34] circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR-194-5p (Vol 21, pg 2145, 2022)
    Zhang, Zhe
    Sun, Chengying
    Zheng, Yan
    Gong, Yanying
    CELL CYCLE, 2024, 23 (03) : 338 - 338
  • [35] To investigate the tumor promotion role of PLOD3 in colorectal cancer and its potential as a prognostic biomarker and therapeutic target
    Dong, Wanhui
    Li, Su
    Tang, Wei
    Sun, Qingming
    Zhu, Pei
    Wang, Mingxing
    Xu, Bin
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [36] Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance (vol 104, pg 16158, 2007)
    Zhou, Jiangbing
    Wulfkuhle, Julia
    Zhang, Hao
    Gu, Peihua
    Yang, Yanqin
    Deng, Jianghong
    Margolick, Joseph B.
    Liotta, Lance A.
    Petricoin, Emanuel, III
    Zhang, Ying
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (49) : 19655 - 19655
  • [37] Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway (vol 280, pg 38932, 2005)
    Park, Sungman
    Kim, Donghwa
    Kaneko, Satoshi
    Szewczyk, Kristen M.
    Nicosia, Santo V.
    Yu, Hua
    Jove, Richard
    Cheng, Jin Q.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (43) : 22844 - 22844
  • [38] Paris saponin VII, a Hippo pathway activator, induces autophagy and exhibits therapeutic potential against human breast cancer cells (vol 43, pg 1568, 2022)
    Xiang, Yu-chen
    Peng, Peng
    Liu, Xue-wen
    Jin, Xin
    Shen, Jie
    Zhang, Te
    Zhang, Liang
    Wan, Fang
    Ren, Yu-liang
    Yu, Qing-qing
    Zhao, Hu-zi
    Si, Yuan
    Liu, Ying
    ACTA PHARMACOLOGICA SINICA, 2025,
  • [39] IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-B pathway in prostate cancer (vol 16, pg 9035, 2017)
    Guo, Yidi
    Zang, Ying
    Lv, Lianzheng
    Cai, Feng
    Qian, Tingting
    Zhang, Guoying
    Feng, Quancheng
    MOLECULAR MEDICINE REPORTS, 2019, 19 (04) : 2970 - 2970
  • [40] L61H46 Shows Potent Efficacy Against Human Pancreatic Cancer Through Inhibiting STAT3 Pathway (vol 10, pg 565, 2018)
    Bai, E.
    Yang, L.
    Xiang, Y.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10683 - 10684
12345